Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 May 22;25(21):4175-82.
doi: 10.1016/j.vaccine.2007.03.007. Epub 2007 Mar 21.

Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans

S Khan  1 , S Chatfield, R Stratford, J Bedwell, M Bentley, S Sulsh, R Giemza, S Smith, E Bongard, C A Cosgrove, J Johnson, G Dougan, G E Griffin, J Makin, D J M Lewis
Affiliations
Clinical Trial

Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans

S Khan et al. Vaccine. .

Abstract

We have evaluated an oral vaccine based on an Salmonella enteric serovar typhi (S. typhi) Ty2 derivative TSB7 harboring deletion mutations in ssaV (SPI-2) and aroC together with a chromosomally integrated copy of eltB encoding the B subunit of enterotoxigenic Escherichia coli heat labile toxin (LT-B) in volunteers. Two oral doses of 10(8) or 10(9)CFU were administered to two groups of volunteers and both doses were well tolerated, with no vaccinemia, and only transient stool shedding. Immune responses to LT-B and S. typhi lipopolysaccharide were demonstrated in 67 and 97% of subjects, respectively, without evidence of anti-carrier immunity preventing boosting of LT-B responses in many cases. Further development of this salmonella-based (spi-VEC) system for oral delivery of heterologous antigens appears warranted.

PubMed Disclaimer

References

    1. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 1988;158(2):372–377. - PubMed
    1. Clemens J.D., Svennerholm A.M., Harris J.R., Huda S., Rao M., Neogy P.K. Seroepidemiologic evaluation of anti-toxic and anti-colonization factor immunity against infections by LT-producing Escherichia coli in rural Bangladesh. J Infect Dis. 1990;162(2):448–453. - PubMed
    1. Clements J.D., El-Morshidy S. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun. 1984;46(2):564–569. - PMC - PubMed
    1. Clements J.D., Lyon F.L., Lowe K.L., Farrand A.L., el-Morshidy S. Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin. Infect Immun. 1986;53(3):685–692. - PMC - PubMed
    1. Maskell D.J., Sweeney K.J., O’Callaghan D., Hormaeche C.E., Liew F.Y., Dougan G. Salmonella typhimurium aroA mutants as carriers of the Escherichia coli heat-labile enterotoxin B subunit to the murine secretory and systemic immune systems. Microb Pathog. 1987;2(3):211–221. - PubMed

Publication types

MeSH terms